1,170
Participants
Start Date
October 15, 2025
Primary Completion Date
April 1, 2027
Study Completion Date
April 1, 2027
(IRIS-CKD Management Program): Education
Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
(IRIS-CKD Management Program): GDMT
Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.
Duke University, Durham
Lead Sponsor
Collaborators (2)
Bayer
INDUSTRY
Boehringer Ingelheim
INDUSTRY
Eli Lilly and Company
INDUSTRY
Duke University
OTHER